LON:VRP - Verona Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 58.50 0.00 (0.00 %) (As of 05/24/2019 04:00 PM ET)Previous CloseGBX 58.50Today's RangeGBX 57.81 - GBX 5952-Week RangeGBX 48 - GBX 165Volume23,673 shsAverage Volume49,797 shsMarket Capitalization£61.65 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom. Receive VRP News and Ratings via Email Sign-up to receive the latest news and ratings for VRP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:VRP Previous Symbol CUSIPN/A CIKN/A Webhttp://www.veronapharma.com/ Phone+44-20-32834200Debt Debt-to-Equity Ratio0.42 Current Ratio10.43 Quick Ratio10.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 51 per share Price / Cash Flow1.15 Book ValueGBX 54.80 per share Price / Book1.07Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees22 Outstanding Shares105,381,000Market Cap£61.65 million Next Earnings DateN/A OptionableOptionable Verona Pharma (LON:VRP) Frequently Asked Questions What is Verona Pharma's stock symbol? Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP." How were Verona Pharma's earnings last quarter? Verona Pharma Plc (LON:VRP) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($14.50) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($23.70) by $9.20. View Verona Pharma's Earnings History. What is the consensus analysts' recommendation for Verona Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verona Pharma. Has Verona Pharma been receiving favorable news coverage? News coverage about VRP stock has been trending positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Verona Pharma earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. Who are some of Verona Pharma's key competitors? Some companies that are related to Verona Pharma include Enochian Biosciences (ENOB), BELLUS Health (BLU), OncoCyte (OCX), OncoCyte (OCX), Pfenex (PFNX), Rafael (RFL), IMV (IMV), MediGene (MDG1), Bioventix (BVXP), Arix Bioscience (ARIX), CorMedix (CRMD), CorMedix (CRMD), BioTime (BTX), BioTime (BTX) and CEL-SCI (CVM). What other stocks do shareholders of Verona Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), VERONA PHARMA P/S (VRNA), Madalena Energy (MVN), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), GRIFOLS S A/S (GRFS) and Innoviva (INVA). Who are Verona Pharma's key executives? Verona Pharma's management team includes the folowing people: Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)Mr. Piers John Morgan, Chief Financial Officer (Age 53)Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)Ms. Victoria Stewart, Director of CommunicationsDr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57) How do I buy shares of Verona Pharma? Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Verona Pharma's stock price today? One share of VRP stock can currently be purchased for approximately GBX 58.50. How big of a company is Verona Pharma? Verona Pharma has a market capitalization of £61.65 million. Verona Pharma employs 22 workers across the globe. What is Verona Pharma's official website? The official website for Verona Pharma is http://www.veronapharma.com/. How can I contact Verona Pharma? Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200. MarketBeat Community Rating for Verona Pharma (LON VRP)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 187 (Vote Outperform)Underperform Votes: 195 (Vote Underperform)Total Votes: 382MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe VRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/25/2019 by MarketBeat.com StaffFeatured Article: What is total return in investing? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.